Hansa Biopharma

Accelerated Immunotherapy Adoption Will Fuel Global Market Expansion

AnalystHighTarget

Not Invested

Consensus Narrative from 3 Analysts

Published

10 Aug 25

Updated

16 Aug 25

AnalystHighTarget's Fair Value

SEK 143.00

77.8% undervalued

16 Aug

SEK 31.70

-26.1%

13.2%

Author's Valuation

SEK 143.0

77.8% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

SEK 143.0

77.8% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

44.61%

Biotech revenue growth rate

12.78%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

5.28%

Calculation

SEK 1.48b

Earnings '28

18.68x

PE Ratio '28

SEK 27.66b

Market Cap '28

SEK 27.66b

Market Cap '28

165.53m

No. shares '28

SEK 167.08

Share Price '28

SEK 167.08 Share Price '28

Discounted to 2025 @ 5.33% p.a.

SEK 143.00

Fair Value '25